Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : The stock approaches again the support level

share with twitter share with LinkedIn share with facebook
09/11/2019 | 03:57am EDT
long trade
Stop-loss triggered
Entry price : 129.9€ | Target : 145€ | Stop-loss : 121.8€ | Potential : 11.62%
Shares in Sartorius Stedim Biotech are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions.
Investors have an opportunity to buy the stock and target the € 145.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : The stock approaches again the support level
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 122.3 support.
  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 43% by 2021.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The stock is in a well-established, long-term rising trend above the technical support level at 111.1 EUR

Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.69 times its estimated earnings per share for the ongoing year.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Stocks mentioned in the article
ChangeLast1st jan.
BYD COMPANY LIMITED -0.39% 103.1 End-of-day quote.165.38%
JUST GROUP PLC 4.22% 44.1285 Delayed Quote.-46.56%
SARTORIUS STEDIM BIOTECH -1.30% 287.4 Real-time Quote.97.29%
WILL GROUP, INC. -1.05% 847 End-of-day quote.-32.35%

share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 1 827 M 2 132 M 2 132 M
Net income 2020 334 M 389 M 389 M
Net Debt 2020 197 M 230 M 230 M
P/E ratio 2020 81,5x
Yield 2020 0,31%
Capitalization 26 861 M 31 209 M 31 341 M
EV / Sales 2020 14,8x
EV / Sales 2021 12,6x
Nbr of Employees 6 690
Free-Float 25,7%
Upcoming event on SARTORIUS STEDIM BIOTECH
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 8
Average target price 246,13 €
Last Close Price 291,40 €
Spread / Highest target 17,4%
Spread / Average Target -15,5%
Spread / Lowest Target -39,3%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH97.29%31 209
ABBOTT LABORATORIES19.10%183 161
MEDTRONIC PLC-9.07%138 669
BECTON, DICKINSON AND COMPANY-17.61%64 954
HOYA CORPORATION11.72%41 420
BAXTER INTERNATIONAL INC.-4.76%40 316